Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
BONE's Cash to Debt is ranked lower than
54% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. BONE: 0.24 )
BONE' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.24

Equity to Asset -0.21
BONE's Equity to Asset is ranked lower than
58% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BONE: -0.21 )
BONE' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.85
Current: -0.21

-0.21
0.85
F-Score: 1
Z-Score: -2.98
M-Score: -3.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -27.24
BONE's Operating margin (%) is ranked higher than
53% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. BONE: -27.24 )
BONE' s 10-Year Operating margin (%) Range
Min: -55.87   Max: -3.49
Current: -27.24

-55.87
-3.49
Net-margin (%) -38.38
BONE's Net-margin (%) is ranked higher than
52% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. BONE: -38.38 )
BONE' s 10-Year Net-margin (%) Range
Min: -126.27   Max: -3.49
Current: -38.38

-126.27
-3.49
ROA (%) -43.95
BONE's ROA (%) is ranked lower than
52% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. BONE: -43.95 )
BONE' s 10-Year ROA (%) Range
Min: -123.5   Max: -11.43
Current: -43.95

-123.5
-11.43
ROC (Joel Greenblatt) (%) -75.88
BONE's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. BONE: -75.88 )
BONE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -253.58   Max: -28.44
Current: -75.88

-253.58
-28.44
Revenue Growth (%) 13.40
BONE's Revenue Growth (%) is ranked higher than
88% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BONE: 13.40 )
BONE' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 40.7
Current: 13.4

0
40.7
EBITDA Growth (%) -34.30
BONE's EBITDA Growth (%) is ranked higher than
54% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. BONE: -34.30 )
BONE' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 2.9
Current: -34.3

0
2.9
EPS Growth (%) -23.80
BONE's EPS Growth (%) is ranked higher than
58% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. BONE: -23.80 )
BONE' s 10-Year EPS Growth (%) Range
Min: 0   Max: 4
Current: -23.8

0
4
» BONE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BONE Guru Trades in

Q3 2013

BONE Guru Trades in Q3 2013

Jim Simons 15,300 sh (New)
» More
Q4 2013

BONE Guru Trades in Q4 2013

Jim Simons 64,100 sh (+318.95%)
» More
Q1 2014

BONE Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BONE



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.92
BONE's P/S is ranked higher than
88% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. BONE: 0.92 )
BONE' s 10-Year P/S Range
Min: 0.55   Max: 19.95
Current: 0.92

0.55
19.95
EV-to-EBIT -5.66
BONE's EV-to-EBIT is ranked higher than
59% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. BONE: -5.66 )
BONE' s 10-Year EV-to-EBIT Range
Min: 260   Max: 366.5
Current: -5.66

260
366.5
Current Ratio 1.89
BONE's Current Ratio is ranked higher than
57% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. BONE: 1.89 )
BONE' s 10-Year Current Ratio Range
Min: 0.74   Max: 6.87
Current: 1.89

0.74
6.87
Quick Ratio 0.98
BONE's Quick Ratio is ranked higher than
51% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. BONE: 0.98 )
BONE' s 10-Year Quick Ratio Range
Min: 0.29   Max: 4.93
Current: 0.98

0.29
4.93

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.50
BONE's Price/Median PS Value is ranked higher than
96% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. BONE: 0.50 )
BONE' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 10.21
Current: 0.5

0.31
10.21
Forward Rate of Return (Yacktman) -18.21
BONE's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. BONE: -18.21 )
BONE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 1.3
Current: -18.21

-0.5
1.3

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States. The Companys products are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, and subcondral bone defect repair in knee and other joint surgeries. Its biologics products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler and cartilage re-generation scaffold; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as is used in conjunction with a hardware plate system. The company’s biologics products also comprise OsteoLock and BacFast facet stabilization dowels that are used to augment spinal procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. It also manufactures and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers coatings for medical devices; OsteoSelect DBM putty, an osteoinductive and osteoconductive product used by surgeons as a bone void filler in the extremities and pelvis; and custom surgical instruments for use with allografts. Further, it sells Via, a surgical drain series used to drain exudate from a surgical site. The company markets its products through various channels, including independent distributors, joint development projects, and direct sales network.
» More Articles for BONE

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: GSVC, PSTB, BONE, ORIT May 09 2011 

More From Other Websites
AngioDynamics (ANGO) Crumbles: Stock Falls 7.4% Jul 25 2014
Bacterin Announces Reverse Split of Common Stock Jul 23 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events,... Jul 23 2014
7:34 am Bacterin International announces 1:10 reverse split of common stock effective at the close... Jul 23 2014
Bacterin Announces Reverse Split of Common Stock Jul 23 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K/A, Results of Operations and Financial... Jul 22 2014
Bacterin Announces Preliminary Second Quarter 2014 Results Jul 21 2014
Bacterin Announces Preliminary Second Quarter 2014 Results Jul 21 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jul 21 2014
Bacterin Announces the Appointment of Robert Di Silvio as President Jul 02 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 01 2014
Bacterin Announces the Appointment of Robert Di Silvio as President Jul 01 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of... Jun 13 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jun 11 2014
Bacterin to Present at the 2014 Newport Coast Securities, Inc. Annual Equity & National Sales... Jun 10 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Financials May 20 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
Bacterin International Holdings' (BONE) CEO Dan Goldberger on Q1 2014 Results - Earnings Call... May 07 2014
BACTERIN INTERNATIONAL HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial... May 06 2014
Bacterin Announces First Quarter 2014 Results May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide